HDAC11 is a novel drug target in carcinomas

International Journal of Cancer

Volumn 132, Issue 9, 2013, Pages 2200-2208

  Deubzer, Hedwig E ^a,b   Schier, Marie C ^a   Oehme, Ina ^a   Lodrini, Marco ^a   Haendler, Bernard ^c   Sommer, Anette ^c   Witt, Olaf ^a,b  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

^c BAYER PHARMA AG   (Germany)

Author keywords

chromatin modulation; colon cancer; histone deacetylase; prostate cancer; targeted therapy

Indexed keywords

CASPASE 3; HISTONE DEACETYLASE; HISTONE DEACETYLASE INHIBITOR; MESSENGER RNA; SHORT HAIRPIN RNA; SMALL INTERFERING RNA; VORINOSTAT;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CATALYSIS; CELL DEATH; CELL PROLIFERATION; CELL STRUCTURE; CELL SURVIVAL; CELL VIABILITY; COLON CARCINOMA; CONTROLLED STUDY; DRUG TARGETING; ENZYME ACTIVITY; ENZYME INHIBITION; GENE EXPRESSION PROFILING; HUMAN; HUMAN CELL; MALIGNANT NEOPLASTIC DISEASE; METABOLIC ACTIVATION; NEUROBLASTOMA; OVARY CANCER; PHENOTYPE; PLASMID; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN FUNCTION; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA EXTRACTION; RNA INTERFERENCE;

APOPTOSIS; BLOTTING, WESTERN; CASPASE 3; CELL PROLIFERATION; CELLS, CULTURED; FLOW CYTOMETRY; HISTONE DEACETYLASE INHIBITORS; HISTONE DEACETYLASES; HUMANS; MAMMARY GLANDS, HUMAN; NEOPLASMS; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SMALL MOLECULE LIBRARIES;

EID: 84874114672     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.27876     Document Type: Article

References (30)

1. Glozak MA, Seto E,. Histone deacetylases and cancer. Oncogene 2007; 26: 5420-32.
2. Yang XJ, Seto E,. The Rpd3/Hda1 family of lysine deacetylases: from bacteria and yeast to mice and men. Nat Rev Mol Cell Biol 2008; 9: 206-18.
3. Haberland M, Montgomery RL, Olson EN,. The many roles of histone deacetylases in development and physiology: implications for disease and therapy. Nat Rev Genet 2009; 10: 32-42.
4. Witt O, Deubzer HE, Milde T, et al. HDAC family: what are the cancer relevant targets? Cancer Lett 2008; 277: 8-21.
5. Witt O, Deubzer HE, Lodrini M, et al. Targeting histone deacetylases in neuroblastoma. Curr Pharm Des 2009; 15: 436-47.
6. Yoo CB, Jones PA,. Epigenetic therapy of cancer: past, present and future. Nat Rev Drug Discov 2006; 5: 37-50.
7. Lyseng-Williamson KA, Yang LP,. Romidepsin: a guide to its clinical use in cutaneous T-cell lymphoma. Am J Clin Dermatol 2012; 13: 67-71.
8. Bolden JE, Peart MJ, Johnstone RW,. Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov 2006; 5: 769-84.
9. Balasubramanian S, Verner E, Buggy JJ,. Isoform-specific histone deacetylase inhibitors: the next step? Cancer Lett 2009; 280: 211-21.
10. Bracker TU, Sommer A, Fichtner I, et al. Efficacy of MS-275, a selective inhibitor of class I histone deacetylases, in human colon cancer models. Int J Oncol 2009; 35: 909-20.
11. Deubzer HE, Lodrini M, Milde T, et al. HDAC11 transcriptionally represses BMP4 to promote neuroblastoma malignancy. In Review.
12. Rhodes DR, Yu J, Shanker K, et al. Oncomine: a cancer microarray database and integrated data-mining platform. Neoplasia 2004; 6: 1-6.
13. Gao L, Cueto MA, Asselbergs F, et al. Cloning and functional characterization of HDAC11, a novel member of the human histone deacetylase family. J Biol Chem 2002; 277: 25748-55.
14. Schmitt M, Pawlita M,. High-throughput detection and multiplex identification of cell contaminations. Nucleic Acids Res 2009; 37: e119.
15. de Ruijter AJ, van Gennip AH, Caron HN, et al. Histone deacetylases (HDACs): characterization of the classical HDAC family. Biochem J 2003; 370: 737-49.
16. Buggy JJ, Sideris ML, Mak P, et al. Cloning and characterization of a novel human histone deacetylase, HDAC8. Biochem J 2000; 350: 199-205.
17. Deubzer HE, Ehemann V, Westermann F, et al. Histone deacetylase inhibitor Helminthosporium carbonum (HC)-toxin suppresses the malignant phenotype of neuroblastoma cells. Int J Cancer 2008; 122: 1891-900.
18. Oehme I, Bosser S, Zornig M,. Agonists of an ecdysone-inducible mammalian expression system inhibit Fas ligand- and TRAIL-induced apoptosis in the human colon carcinoma cell line RKO. Cell Death Differ 2006; 13: 189-201.
19. Egner U, Krätzschmar J, Kreft B, et al. The target discovery process. Chembiochem 2005; 6: 468-79.
20. Kelly WK, O'Connor OA, Krug LM, et al. Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer. J Clin Oncol 2005; 23: 3923-31.
21. Haberland M, Montgomery RL, Olson EN,. The many roles of histone deacetylases in development and physiology: implications for disease and therapy. Nat Rev Genet 2009; 10: 32-42.
22. Burgess AW, Faux MC, Layton MJ, et al. Wnt signaling and colon tumorigenesis-a view from the periphery. Exp Cell Res 2011; 317: 2748-58.
23. Peters JM, Shah YM, Gonzalez FJ,. The role of peroxisome proliferator-activated receptors in carcinogenesis and chemoprevention. Nat Rev Cancer 2012; 12: 181-95.
24. Becker JC, Fukui H, Imai Y, et al. Colonic expression of heme oxygenase-1 is associated with a better long-term survival in patients with colorectal cancer. Scand J Gastroenterol 2007; 42: 852-8.
25. Huang MC, Chen HY, Huang HC, et al. C2GnT-M is downregulated in colorectal cancer and its re-expression causes growth inhibition of colon cancer cells. Oncogene 2006; 25: 3267-76.
26. Lee HJ, Pyo JO, Oh Y, et al. AK2 activates a novel apoptotic pathway through formation of a complex with FADD and caspase-10. Nat Cell Biol 2007; 9: 1303-10.
27. Zeng YX, Somasundaram K, el-Deiry WS,. AP2 inhibits cancer cell growth and activates p21WAF1/CIP1 expression. Nat Genet 1997; 15: 78-82.
28. Lombardo Y, Scopelliti A, Cammarareri P, et al. Bone morphogenetic protein 4 induces differentiation of colorectal cancer stem cells and increases their response to chemotherapy in mice. Gastroenterology 2011; 140: 297-309.
29. Glozak, MA, Seto E,. Acetylation/deacetylation modulates the stability of DNA replication licensing factor Cdt1. J Biol Chem 2009; 284: 11446-53.
30. Villagra A, Cheng F, Wang HW, et al. The histone deacetylase 11 regulates the expression of interleukin 10 and immune tolerance. Nat Immunol 2009; 10: 92-100.